IMCD, a global leader in the distribution and formulation of specialty chemicals and ingredients, announced its financial results for the first nine months of 2025.

IMCD reported an operating EBITA of €394 million, reflecting a 2 per cent decline compared with the same period in 2024, or a 1 per cent increase on a constant currency basis. Gross profit rose by 2 per cent to €927 million, and by 5 per cent on a constant currency basis, supported by a combination of organic growth, successful acquisitions and resilient gross profit margins.

Free cash flow stood at €284 million compared with €299 million in the first nine months of 2024, while cash earnings per share were €4.16 versus €4.67 in the same period last year.

During the reporting period, IMCD continued to strengthen its global footprint through six completed acquisitions and the signing of two additional transactions, reinforcing its presence in key strategic markets.

Marcus Jordan, Chief Executive Officer of IMCD, commented: “Despite continued macroeconomic challenges, we are pleased with our gross profit growth during the first nine months of 2025. Our performance reflects the strength of our asset-light business model and the dedication of our teams, who remain focused and energised. We are intensifying efforts to enhance cost efficiency and drive commercial excellence across our organisation. Although global trade uncertainties and tariff discussions persist, we remain confident in our long-term strategy. With our speciality-focused portfolio, geographic and market diversity, and advanced digital and supply chain capabilities, IMCD is well positioned for sustainable growth in the years ahead.”